whitepaper

Product hub: Introducing the latest addition to Thermo Fisher Scientific’s genome editing portfolio – InvitrogenTM TrueCutTM HiFi Cas9 Protein!

Read about the latest addition Invitrogen™ TrueCut™ HiFi Cas9 Protein to support your application and research goals.

The CRISPR-Cas9 genome editing system has seen exponential growth in adoption with broad applications from basic research to therapeutics. The system is composed of Cas9 nuclease and a target-specific guide RNA (gRNA) that, as a complex, induces a double stranded DNA break at a desired location. While the wild type Cas9 protein can achieve high editing efficiencies, the CRISPR-Cas9 system can inherently cleave the target DNA at unintended locations (known as off-target events) that can result in undesired phenotypes or loss of functional gene activity. Off-target events are especially detrimental for therapeutic applications where improved specificity is critical.

Send this to a friend